Investors Capital Advisory Services’s TherapeuticsMD TXMD Stock Holding History

Investors Capital Advisory Services’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-386	Closed	-$121K	–	713
2014 Q1	$121K	Buy	+386	New	+$123K	0.03%	591

Other funds holding TXMD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Investors Capital Advisory Services's TXMD Position: Q2 2014 in Review

Investors Capital Advisory Services sold out of TherapeuticsMD (TXMD) in Q2 2014, closing a stake of 386 shares — an estimated $121K sold.

Investors Capital Advisory Services first reported a position in TXMD in Q1 2014 and held it in 1 quarter. The position peaked at $121K in Q1 2014. 87 funds tracked by Wall St. Rank hold TXMD as of Q2 2014.

Investors Capital Advisory Services reported no remaining TherapeuticsMD position as of Q2 2014 after selling out during the quarter.
Investors Capital Advisory Services sold 386 TherapeuticsMD shares in Q2 2014, an estimated $121K.
Investors Capital Advisory Services first reported a position in TherapeuticsMD in Q1 2014 and held it in 1 quarter.
Investors Capital Advisory Services's TherapeuticsMD position peaked at $121K in Q1 2014.
87 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2014.

Based on Investors Capital Advisory Services's 13F filing for Q2 2014, filed 14 Aug 2014.